Pay in 4 interest-free payments of $5.21 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
These 3.8 million met the clinical criteria for the Bridge program, did not have a diagnosis of type 2 diabetes, sleep apnea or MASH, did not have a GLP-1 Part D covered prescription in 2023 and "could be eligible for the Medicare GLP-1 Bridge, assuming no changes in diagnosis or GLP-1 use in Part D in 2026," the report added
While the Canadian market is many times smaller than the U.S., the Danish pharma is still expecting the generic pressure to represent a material impact
Contamination risk is low with proper technique, but it's higher than a purpose-built clinical setting
The competitive landscape intensifies as pharmaceutical giants invest heavily in next-generation GLP-1 analogs with improved efficacy profiles
Galea I
